氧化芍药苷
氧化芍药苷 性质
| 熔点 | >162°C (dec.) |
|---|---|
| 沸点 | 737.1±60.0 °C(Predicted) |
| 密度 | 1.71±0.1 g/cm3(Predicted) |
| 储存条件 | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| 溶解度 | 可溶于DMSO（少许）、甲醇（少许） |
| 形态 | 固体 |
| 酸度系数(pKa) | 8.16±0.15(Predicted) |
| 颜色 | 白色至浅黄色 |
| 稳定性 | 吸湿性 |
氧化芍药苷 用途与合成方法
Oxypaeoniflorin (OPA; 0.1-10 µM; 8 hours) obviously reversed the hypoxia/reoxygenation (H/R)-induced decrease in cell activity and increase in apoptosis of H9c2 cells. Oxypaeoniflorin inhibits apoptosis by activating the Sirt1 (silent information regulator factor 2 related enzyme 1)/Foxo1(forkhead transcription factor FKHR) signaling pathway in myocardial tissues and H9c2 cells.
Oxypaeoniflorin (0-30 μM) attenuates inflammatory effects via regulation of the toll-like receptor (TLR), extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases signaling pathways in LPS-stimulated RAW264.7 cells.
Oxypaeoniflorin (OPA; 10-40 mg/kg; intragastrical administration; every day; for 30 days) treatment significantly reduces disruption of cardiac function and improves the indicators of ejection fraction (EF) and fractional shortening (FS). Oxypaeoniflorin significantly reduces the release of myocardial infarction-related factors, such as the creatine kinase (CK-MB), cardiac troponin I (cTnI) and cardiac troponin T (cTnT).
| Animal Model: | C57BL/6 male mice (6-8 weeks of age, 20-25 g) bearing myocardial ischemia/reperfusion (MI/R) injury |
| Dosage: | 10 mg/kg, 20 mg/kg, 40 mg/kg |
| Administration: | Intragastrical administration; every day; for 30 days |
| Result: | Significantly reduced disruption of cardiac function and improved the indicators of ejection fraction (EF) and fractional shortening (FS). |
药理药效:有抗炎镇痛、调节免疫、治疗风湿性关节炎等作用
氧化芍药苷 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-N0748 | 1 mg | 660 | ||
| 2024-01-25 | HY-N0748 | 氧化芍药苷 | 39011-91-1 | 5mg | 1650 |
